Prostate Cancer
TRAVERSE: Men using testosterone replacement do not have increased risk for CV events
CHICAGO — Older men with hypogonadism and high risk for cardiovascular disease who received testosterone therapy had similar rates of CV events as those who received placebo, according to findings from the TRAVERSE trial.
Number of cancer survivors diagnosed with new malignancies increases 15%
The number of cancer survivors diagnosed with a new malignancy increased by 15% from 2013 to 2019, according to data published in JAMA Oncology.
Talazoparib regimen improves outcomes among subset of men with metastatic prostate cancer
CHICAGO — Adding talazoparib to enzalutamide reduced the risk for disease progression or death by 55% in certain men with metastatic castration-resistant prostate cancer, results of the randomized phase 3 TALAPRO-2 trial showed.
FDA approves Lynparza regimen for certain men with BRCA-positive prostate cancer
The FDA approved olaparib in combination with abiraterone acetate and prednisone or prednisolone for men with suspected deleterious or deleterious BRCA-mutated metastatic castration-resistant prostate cancer.
Q&A: Lack of diversity in clinical trials hinders understanding of prostate cancer
Ethnic and racial disparities exist and persist in many areas of oncology and must be addressed to promote and ensure health equity.
FDA news: Colorectal, prostate cancer treatments receive fast track designations
The FDA announced several regulatory actions the past few weeks.
Researchers use CAR T-cell therapy to pursue new prostate cancer target
An immunotherapy regimen featuring a novel chimeric antigen receptor T-cell therapy demonstrated antitumor activity against metastatic prostate cancer models, study results published in Nature Communications showed.
Prostate cancer among transgender women may be more common than thought
Prostate cancer may be more common among transgender women than case reports suggest, according to a study published in JAMA that estimated risk at approximately 14 cases per 10,000 people.
For some men, delaying salvage therapy after prostate cancer surgery boosts mortality risk
Delaying salvage radiation therapy after radical prostatectomy for men with just one high-risk factor for prostate cancer recurrence may significantly increase risk for all-cause mortality, a study in Journal of Clinical Oncology showed.
AI model uses physician notes to predict survival after cancer diagnosis
Researchers from University of British Columbia have developed an artificial intelligence model that can accurately predict survival after a cancer diagnosis using physician notes from an initial oncology consult.